{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:37:45Z","timestamp":1785879465167,"version":"3.56.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"US Government National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaadreviews.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jdrv.2024.12.008","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T17:13:44Z","timestamp":1734628424000},"page":"51-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Pediatric psoriasis: Biologics and oral small molecule inhibitors in modern therapy"],"prefix":"10.1016","volume":"3","author":[{"given":"Alexandra","family":"Firek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Castelo-Soccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jdrv.2024.12.008_bib1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdrv.2024.12.008_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/PPA.S350753","article-title":"Secukinumab for the treatment of psoriasis in pediatrics: patient selection and acceptability","volume":"17","author":"Narbutt","year":"2023","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jdrv.2024.12.008_bib3","first-page":"121","article-title":"Psoriasis in children","volume":"6","author":"Pinson","year":"2016","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.jdrv.2024.12.008_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.896550","article-title":"Efficacy and safety of biological agents for the treatment of pediatric patients with psoriasis: a bayesian analysis of six high-quality randomized controlled trials","volume":"13","author":"Cai","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jdrv.2024.12.008_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdrv.2024.12.008_bib6","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3892\/etm.2021.10864","article-title":"Management of psoriasis in children (review)","volume":"22","author":"Branisteanu","year":"2021","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jdrv.2024.12.008_bib7","first-page":"25","article-title":"Management of psoriasis in adolescence","volume":"5","author":"Fotiadou","year":"2014","journal-title":"Adolesc Health Med Ther"},{"issue":"9","key":"10.1016\/j.jdrv.2024.12.008_bib8","first-page":"1201","article-title":"Biologics for pediatric moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis","volume":"20","author":"Huang","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"10.1016\/j.jdrv.2024.12.008_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40257-013-0026-8","article-title":"Diagnosis and treatment of pediatric psoriasis: current and future","volume":"14","author":"Shah","year":"2013","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jdrv.2024.12.008_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1529-8019.2008.01214.x","article-title":"Pediatric psoriasis: updates in biologic therapies","volume":"22","author":"Sukhatme","year":"2009","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.jdrv.2024.12.008_bib11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjd.19147","article-title":"Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)","volume":"183","author":"Paller","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jdrv.2024.12.008_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40272-021-00443-5","article-title":"Targeted therapy for pediatric psoriasis","volume":"23","author":"Nogueira","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"11","key":"10.1016\/j.jdrv.2024.12.008_bib13","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2022.15632","article-title":"Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials","volume":"328","author":"Lebwohl","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jdrv.2024.12.008_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40272-023-00592-9","article-title":"Topical management of pediatric psoriasis: a review of new developments and existing therapies","volume":"26","author":"Lie","year":"2024","journal-title":"Paediatr Drugs"},{"issue":"2","key":"10.1016\/j.jdrv.2024.12.008_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13555-016-0117-6","article-title":"Systemic treatment of pediatric psoriasis: a review","volume":"6","author":"Napolitano","year":"2016","journal-title":"Dermatol Ther"},{"issue":"8","key":"10.1016\/j.jdrv.2024.12.008_bib16","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/biomedicines9080940","article-title":"Pediatric psoriasis: from new insights into pathogenesis to updates on treatment","volume":"9","author":"Kim","year":"2021","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.jdrv.2024.12.008_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jaad.2019.08.019","article-title":"Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study","volume":"82","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jdrv.2024.12.008_bib18","article-title":"Pediatric dermatology-critical approach to the new treatments","volume":"32","author":"Liang","year":"2019","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jdrv.2024.12.008_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14740338.2023.2173170","article-title":"Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients","volume":"22","author":"Megna","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"10.1016\/j.jdrv.2024.12.008_bib20","first-page":"103","article-title":"Biologic treatment options for pediatric psoriasis and atopic dermatitis","volume":"6","author":"Cline","year":"2019","journal-title":"Children (Basel)"},{"key":"10.1016\/j.jdrv.2024.12.008_bib21","series-title":"Chronic Moderate to Severe Plaque Psoriasis in Children Ages 4 to 17. Dose: 0.8 mg\/kg Weekly, With a Maximum of 50 mg per Week","year":"2023"},{"issue":"5","key":"10.1016\/j.jdrv.2024.12.008_bib22","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jaad.2010.04.004","article-title":"Long-term etanercept in pediatric patients with plaque psoriasis","volume":"63","author":"Paller","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jdrv.2024.12.008_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jdrv.2024.12.008_bib24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14740338.2020.1752659","article-title":"Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation","volume":"19","author":"Zangrilli","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"10089","key":"10.1016\/j.jdrv.2024.12.008_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jdrv.2024.12.008_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/PHMT.S75836","article-title":"Efficacy and safety of ustekinumab in adolescents","volume":"7","author":"Kellen","year":"2016","journal-title":"Pediatric Health Med Ther"},{"issue":"6","key":"10.1016\/j.jdrv.2024.12.008_bib27","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jdrv.2024.12.008_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdrv.2024.12.008_bib29","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jaad.2023.11.068","article-title":"Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial","volume":"90","author":"Fiorillo","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdrv.2024.12.008_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdcr.2015.12.005","article-title":"Pediatric psoriasis treated with apremilast","volume":"2","author":"Smith","year":"2016","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jdrv.2024.12.008_bib31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/ajd.13864","article-title":"Mental health, insomnia and suicidal ideation during treatment with apremilast","volume":"63","author":"Cowan","year":"2022","journal-title":"Australas J\u00a0Dermatol"},{"issue":"3","key":"10.1016\/j.jdrv.2024.12.008_bib32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.annder.2017.01.004","article-title":"[Apremilast: beware of suicidal ideation and behaviour]","volume":"144","author":"Schmutz","year":"2017","journal-title":"Ann Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jdrv.2024.12.008_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdrv.2024.12.008_bib34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdrv.2024.12.008_bib35","first-page":"19","article-title":"Effectiveness and safety of deucravacitinib for the management of psoriasis: a review of the current literature","volume":"13","author":"Potestio","year":"2023","journal-title":"Psoriasis (Auckl)"}],"container-title":["JAAD Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295019892400062X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295019892400062X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T01:09:05Z","timestamp":1746234545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295019892400062X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":35,"alternative-id":["S295019892400062X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdrv.2024.12.008","relation":{},"ISSN":["2950-1989"],"issn-type":[{"value":"2950-1989","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric psoriasis: Biologics and oral small molecule inhibitors in modern therapy","name":"articletitle","label":"Article Title"},{"value":"JAAD Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdrv.2024.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Dermatology.","name":"copyright","label":"Copyright"}]}}